Kimco Realty: “Diamond in the Rough”

MoneyShow  |

I view this washout in the retail sector as a prime opportunity for dividend investors to take a position in a truly blue-chip stock trading at a steep discount, asserts Bryan Perry, dividend investing expert and editor of Cash Machine.

Kimco Realty (KIM) is North America’s largest publicly traded owner and operator of open-air shopping center, with over a 50-year history in shopping center acquisitions, development, and management.

It is geographically diversified across 35 states 534 U.S. shopping centers comprising 86 million square feet. It boasts a 95.1% occupancy rate with only 15 tenants with exposure greater than 1.0%

The biggest reason to buy Kimco Realty is that the company has increased its funds from operations and dividends on a consistent basis in the past. For income investors, this has a lot of value.

The real estate investment trust increased its dividend from $0.64 a share in 2010 to $1.02 a share in 2016. In fourth-quarter 2016, the company handed shareholders a 6% dividend increase.

This REIT pays 6.0%. Its share price has declined some 56% during the past 10 months. Let’s do a little deep-value investing in a sector where there are some diamonds in the rough that have rock-solid dividends at levels not seen in years.

The company raised its annual dividend payout by 3 cents to $1.08 per share, or 27 cents per quarter. The next ex-dividend date is July 3 to be entitled to the next payment date slated for July 17.

Bryan Perry is Editor of Cash Machine, Premium Income, Quick Income Trader and Dividend Investing Weekly.

Subscribe to Cash Machine here…

About MoneyShow.com: Founded in 1981, MoneyShow is a privately held financial media company headquartered in Sarasota, Florida. As a global network of investing and trading education, MoneyShow presents an extensive agenda of live and online events that attract over 75,000 investors, traders and financial advisors around the world.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.